Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia by Ascher-Svanum, Haya et al.
Clinical, Functional, and Economic Ramiﬁcations of Early Nonresponse to
Antipsychotics in the Naturalistic Treatment of Schizophrenia
Haya Ascher-Svanum
1,2, Allen W. Nyhuis
2, Douglas
E. Faries
2, Bruce J. Kinon
2, Robert W. Baker
2, and
Anantha Shekhar
3
2Eli Lilly and Company, DC 4133, Indianapolis, IN 46285;
3DepartmentofPsychiatry,IndianaUniversitySchoolofMedicine,
Indianapolis, IN
Objective: Early nonresponse to antipsychotics appears to
predict subsequent nonresponse to treatment when assessed
in randomized controlled trials of predominately acute
inpatients treated for schizophrenia. This study assessed
the predictive accuracy of early nonresponse to treatment
and its clinical, functional, and economic ramifications in
the naturalistic treatment of predominately chronic outpa-
tients treated for schizophrenia. Methods: This post hoc
analysis used data from a 1-year, randomized, open-label
study of olanzapine, risperidone, and typical antipsychotics
in the treatment of schizophrenia. If clinically warranted,
patients could switch antipsychotics following 8 weeks of
treatment. Patients completing 8 weeks of treatment
(n 5 443 of 664 enrollees) were included. Patients with
early response (‡20% improvement from baseline on the
Positive and Negative Syndrome Scale at 2 weeks) were
compared with early nonresponders on symptom remission,
functionality, perceptions of medication influence, and to-
tal health care costs at 8 weeks. Results: Early response/
nonresponse at 2 weeks predicted subsequent response/
nonresponse at 8 weeks with a high level of accuracy
(72%) and specificity (89%). After 8 weeks, early non-
responders were less likely to achieve symptom remission
(P < .001), improved less on functional domains (P <
.05), perceived medication as less beneficial (P 5 .004),
and incurred total heath care costs over twice that of
early responders ($4349 vs $2102, P 5 .010). Conclusions:
In the usual care of schizophrenia patients, early non-
response appears to reliably predict subsequent non-
response to continued treatment with the same
medication to be associated with poorer outcomes and
higher health care costs. Identifying early nonresponders
may minimize prolonging exposure to suboptimal or inef-
fective treatment strategies.
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Introduction
Clinicians have long believed in a delayed onset of the
action of antipsychotic drugs and assumed there is
a need to reassess the choice of an antipsychotic only af-
ter 4–8 weeks of treatment.
1–6 This ‘‘delayed onset’’
hypothesis was questioned long ago,
7 but interest in
formally testing this hypothesis was recently rekindled
by a meta-analysis
8 of 42 controlled randomized
clinical trials (RCTs) in the treatment of predominately
acutely ill inpatients with schizophrenia. This meta-
analysis found that a larger reduction of symptoms
occurs during the first 2 weeks than during the rest of
the 4-week treatment period with the same antipsychotic
agent. Additional post hoc analyses of RCT data in the
treatment of predominately acute inpatients with schizo-
phrenia
9–11 have also shown that early nonresponse—as
early as 1 or 2 weeks—can reliably predict sub-
sequent nonresponse to treatment of schizophrenia
with antipsychotics.
Most prior research has used data from subjects
enrolled in randomized, double-blind, clinical trials that
differ substantially from those treated with open label
in routine care.
12 RCTs typically exclude subjects with
comorbid disorders, especially comorbid substance abuse
and medical conditions, and often account for less than
14% of all schizophrenic patients in the same clinical fa-
cilities.
13 Furthermore, previous studies
9–11,14 were initi-
ated at inpatient settings, thus, possibly confounded by
nonspecific effects of hospitalization during the initial
phasesofthestudies.
10Theauthorsthemselveshavenoted
such limitations leading to an inability to generalize
these findings to patients treated in routine outpatient
settings. Thus, if findings from RCTs with acutely ill
inpatients can be replicated in the usual treatment of
chronically ill outpatients with schizophrenia, the gener-
alization of the findings may have important clinical,
functional, and economic implications for the treatment
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1163ofpatientswithschizophreniainoutpatientclinicalpractice,
including enhancement of clinicians’ ability to limit pro-
longed exposure to subtherapeutic or ineffective antipsy-
chotic treatment regimens.
To address this scientific gap and expand prior re-
search to chronically ill outpatients treated in a usual
care setting, we performed a post hoc analysis using
data from a practical, randomized, open-label, multisite,
naturalistic study of antipsychotics in the treatment of
schizophrenia in the United States that had broad inclu-
sion criteria and did not exclude patients with comorbid
medical or psychiatric conditions. We first calculated
conditional probabilities—as did prior studies
9–11—to
examine whether early response/nonresponse to antipsy-
chotic medication (at 2 weeks of treatment) accurately
predicts subsequent response to treatment (following
8 weeks of treatment). We aimed to assess whether pre-
viously reported findings, using data from double-blind
trials with predominately acutely ill inpatients, can be
replicated when treatment is open label and is provided
to predominately chronically ill outpatients. We used
2 response criteria, a relative and an absolute response
criterion, because relative responsecriteria are vulnerable
to the effect of baseline scores. We then compared
early responders and early nonresponders on subse-
quent clinical, functional, and economic outcomes after
8 weeks of continued therapy with the same antipsy-
chotic agents.
Methods
Participants
Data for this post hoc analysis were drawn from a 1-year,
Lilly-sponsored, practical, randomized, open-label, mul-
tisite, cost-effectiveness study (N = 664) of olanzapine,
risperidone, and typical antipsychotics in the treatment
of schizophrenia (HGGD). The primary results of this
study were previously published.
15 Participants were at
least 18 yearsold meeting Diagnostic and Statistical Man-
ual of Mental Disorders, Fourth Edition, criteria for
schizophrenia, schizoaffective disorder, or schizophreni-
form disorder and met a symptom threshold of 18 or
more on the Brief Psychiatric Rating Scale
16 derived
from the Positive and Negative Syndrome Scale
(PANSS).
17 In order to enhance generalizability of study
results to treatment in usual care settings, the study inclu-
sion criteria were broad allowing enrollment of subjects
with substance abuse or other psychiatric and medical
comorbidities, unless the condition was very serious
and needed immediate attention. Enrollees were chroni-
cally ill individuals; almost all outpatients (95%) who
weredeemedbytheirtreatingphysicianstorequireamed-
ication change primarily due to poor efficacy of prior
medication. A few participants were also eligible to enroll
in the study if a treatment change was required due to
medication intolerability. Participants had about 17
years since first psychiatric hospitalization, and their
illness severity was at least moderately severe as indicated
by the moderately high PANSS total score (mean 86.9,
SD = 19.8).
18 About one-third of the sample (31%)
had a psychiatric hospitalization in the past year, and
most were unemployed (81%).
15
The study was completed in September 2002 and con-
ductedat21sitesacross15statesintheUnitedStates.The
protocol and consent procedures were approved by insti-
tutional review boards, and after a complete description
of the study was given to the subjects, signed consent
forms were obtained from patients prior to participa-
tion in the study. Almost all participants (95%) were
outpatients at the time of enrollment. Patients were
randomized to open-label treatment with olanzapine
(N = 229), typical antipsychotics of physician’s choice
(N = 214),orrisperidone(N = 221).Subjectscould,ifclin-
ically warranted, be switched from the initial randomized
antipsychoticdrugafteraminimumof8weeksoftherapy.
Measures
The current analysis included subjects who had PANSS
scores at both Week 2 and Week 8 of the study and com-
pleted the first 8 weeks of treatment on their initially ran-
domized antipsychotic, thus excluding patients who
switched medication prior to Week 8, discontinued the
study prior to Week 8, and those who did not have
PANSS scores at Week 2 or 8. The analytical sample
(443 or 66.7% of 664 enrollees) reflects selective attrition
in which switching was responsible for about one-fourth
of the attrition rate (50 of 221, or 23%). Switching was
primarily due to adverse events (22 or 44%), patient re-
quest (12 or 24%), and lack of efficacy (10 or 20%). An-
other one-fourth of the attrition rate was due to patients
discontinuing the study (54 of 221 or 24%) for various
reasons, primarily due to patient decision (21 of 54 or
39%), lost to follow-up (12 of 54 or 22%), and physician
decision(11of54or20%).Therestoftheattrition(117of
221 or 53%) was due to missing PANSS scores at Week 2
or 8. Per protocol, patients continued in the study even if
missed assessments.
Subjects were defined as ‘‘early responders’’ if they ex-
perienced at least 20% improvement (decrease) on the
PANSS total score from baseline (‘‘minimal improve-
ment’’)
18 at 2 weeks of treatment, and ‘‘early nonres-
ponders’’ were subjects who failed to achieve this level
of symptom improvement at 2 weeks. At the end of 8
weeks of treatment, all subjects were classified as either
‘‘responders’’ or ‘‘nonresponders’’ based on the same cri-
teria used at 2 weeks.
In addition to assessing the accuracy of early response/
nonresponse at 2 weeks as a predictor of subsequent re-
sponse/nonresponse to treatment at 8 weeks, the early
responders were compared with early nonresponders
on symptom remission, levels of functioning, patients’
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health care costs. The definition of symptom remission
was based on the Schizophrenia Working Group expert
consensus criteria,
19 which define remission as a score
of mild or better (3 or less) on 8 PANSS items: delusions
(P1), conceptual disorganization (P2), hallucinatory be-
havior (P3), unusual thought content (G9), mannerisms
and posturing (G5), blunted affect (N1), passive/apa-
thetic social withdrawal (N4), and lack of spontaneity
and flow of conversation (N6). Although this definition
also requires maintaining mild symptom severity level for
at least 6 months (severity and duration criteria), we used
only the severity criterion because the current analysis
was limited to the first 8 weeks of treatment. Levels of
functioning were assessed with the Medical Outcome
Survey-Short Form 36 (SF-36),
20 a patient-rated scale
assessing physical and mental health functioning on
8 subscales and also providing 2 composite scores—for
mental health and for physical health functioning.
Patients’ attitudes and behavioral factors influencing
their adherence with antipsychotic medication were
assessed with the Rating of Medication Influences
(ROMI).
21 The scale includes 9 items depicting reasons
for medication adherence and 10 items with reasons
for nonadherence, each rated on a 3-point scale from
none (1) to strong (3). ROMI items were found to repre-
sent 5 underlying factors: negative aspects of medication,
denial of illness, positive external influence, perceived
medication benefit, and stigma.
22 In addition, the ‘‘per-
ceived medication benefit’’ factor was found to be the
only strong predictor of treatment duration among the
5 underlying dimensions of medication influence. Higher
levels of perceived beneficial effect of medication were as-
sociated with reduced risk of early treatment discontinu-
ation, and patients with greater beliefs in the beneficial
effect of their medication had greater symptom improve-
ments and were more satisfied with their quality of life.
22
Because the parent study
15 was a cost-effectiveness
study, it included systematic abstraction of resource uti-
lization from patients’ medical records, which provided
data for calculating total direct health care costs for
each patient. The economic analysis was conducted
from the perspective of the public payer health care sys-
tem, thus including only direct medical costs. Included
were costs of treatment resources considered to be ‘‘men-
tal health’’ (eg, antipsychotic and other psychotropic
medications, psychiatric hospitalizations, outpatient vis-
its to psychiatrists, etc) as well as those considered to be
‘‘nonpsychiatric’’ resources (eg, nonpsychotropic medi-
cations, hospitalizations for physical illnesses, primary
care physician visits, nonprotocol laboratories). With
information from patient report, medical records, and
administrative databases, site personnel completed the
resource utilization forms. Units of specific service use
for individual patients were documented and coded
(but not assigned costs) at each study site. Medicare pub-
lic data (based on 2001 national average charge and
payment schedules) were used as a costing benchmark.
A summary of unit costing sources for each resource
component can be found in a previous publication.
15
Thesecostdatawereusedtocalculatethecostforthefirst
8 weeks of treatment for each patient.
Statistical Analysis
Rates of early response and early nonresponse were cal-
culated for all patients at 2 weeks and 8 weeks of treat-
ment.Thesensitivity, specificity,positivepredictive value
(PPV), negative predictive value (NPV), and overall pre-
dictive accuracy were calculated based on early response/
early nonresponse at 2 weeks and subsequent response/
nonresponse at 8 weeks. Sensitivity was defined as the
conditional probability that a responder is correctly iden-
tified, ie, the proportion of 8-week responders correct-
ly identified at 2 weeks. Specificity was defined as the
conditional probability that a nonresponder is correctly
identified, ie, the proportion of 8-week nonresponders
correctly identified at 2 weeks. PPV provided confidence
in predicted positive values, defined as the proportion of
patients who were responders at 8 weeks among those
classified as responders at 2 weeks. NPV provided confi-
dence in predicted negative values, defined as the propor-
tion of patients who were nonresponders at 8 weeks
among those classified as nonresponders at 2 weeks.
(NPV is of greater practical interest because nonrespond-
ers are targeted for medication change.) Predictive
accuracy—an overall measure of performance of the re-
sponse marker—was defined as the proportion of
patients whose 2-week status (early response or nonearly
response) accurately predicted their 8-week status.
To assess robustness of the findings, we conducted
a sensitivity analysis in which the analysis was repeated
using an absolute (rather than a relative) definition of
early response/early nonresponse
9: mild or better score
(3 or less) on all 4 PANSS psychotic items (unusual
thought content, suspiciousness, hallucinations, and con-
ceptual disorganization).
In addition, the 2 patient groups (early responders and
early nonresponders) were compared on change from
baseline to 8 weeks of treatment on rates of symptom
remission,levelsoffunctioning(perSF-36),andtotaldirect
health care costs. Patients’ perceptions of medication in-
fluence on adherence were compared using the ROMI,
but because this measure was not assessed at baseline,
change scores from baseline were not feasible and group
comparisonswereconductedonlyforthe8-weektimepoint.
Comparisons of early responders and early nonres-
pondersduringthe first 2weeks of treatmentand on their
changes from baseline to 8 weeks on symptom remission
rates, level of functioning, perceptions of medication
influence, and health care costs were conducted using
unpaired t test, chi-square test, Fisher exact test, and the
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metric bootstrap resampling (with 10 000 replications)
was used to validate the results. A 2-sided alpha level
of .05 was used for tests of significance. Covariate-
adjusted comparisons were made using logistic regres-
sion and analysis of covariance. Covariates included
age, gender, ethnicity, PANSS total score at baseline, ill-
ness duration, duration of hospitalization in the year
prior to enrollment, current substance abuse diagnosis,
and having health insurance or not. Covariates were
identified a priori as those associated with differential
outcomes in the treatment of schizophrenia.
23,24 The
analysis did not use assigned antipsychotic as a covariate
due to the design of the study in which patients could be
switched to another antipsychotic if warranted per clini-
cian’s judgment. As reported in the primary publication
of the parent study,
15 a significantly larger proportion
of patients randomized to conventional antipsychotics
and risperidone were switched to another antipsychotic
compared with patients randomized to olanzapine
(14%olanzapine,31%risperidone,and53%conventional,
P < .001). Thus, there are potential complications with
interpretation of such data—especially for analyses
involving the 8-week data.
25
Results
Patient Baseline Characteristics
Baseline characteristics of early responders (N = 98,
22.1%) and early nonresponders (N = 345, 77.9%) are
presented in table 1. The 2 groups did not significantly
differ on any of the 29 baseline demographic or clinical
characteristics with the exception of baseline PANSS to-
tal score, PANSS impulsivity/hostility, and PANSS anx-
iety/depression subscales on which early responders had
a significantly higher baseline symptom severity score
than early nonresponders. Baseline values are not avail-
able for ROMI scores because it was notassessed at base-
line. Similarly, health care costs were not assessed for the
period just prior to enrollment (‘‘baseline’’).
Patients who were included in these analyses did not
significantly differ from excluded patients on most base-
line characteristics including age, gender, race, employ-
ment, PANSS total score, past year psychiatric hospital
duration, inpatient at study start, duration of psychiatric
diagnosis, age at onset of diagnosis, and health insurance.
However, the excluded patients were significantly more
likely to be married (24% vs 15%, P = .002) and had
a significantly higher mean (SD) number of prior episodes
[7.6 (11.2) vs 6.6 (9.1), P = .041].
Predicting Subsequent Response
Early response or nonresponse—following 2 weeks of
treatment—was found to accurately predict subsequent
response or nonresponse at 8 weeks because most
(71.8%) of the eventual responders and nonresponders
after 8 weeks of treatment with a typical or an atypical
antipsychotic were correctly identified after 2 weeks of
treatment with the same antipsychotic agent. The per-
centage of patients who were responders and nonres-
ponders at both time points (2 and 8 weeks) was
14.9% and 56.7%, respectively. The overall accuracy level
(71.8%) reflects the combination of these 2 groups.
Specificity level was high (88.7%), indicating a high prob-
ability that nonresponders are correctly identified,
accompanied by moderate sensitivity (41.5%, probability
that responders are correctly identified), moderate PPV
(67.4%), and high NPV (73.0%).
A sensitivity analysis, which employed an absolute
definition of response (mild or better score on 4 PANSS
psychotic items), replicated the findings. Using this
secondary response definition, patients were identified
as early responders (N = 167, 37.7%) or nonresponders
(N = 276,62.3%), and most (75.6%%)of theeventual res-
ponders or nonresponders after 8 weeks of treatment
with a typical or an atypical antipsychotic were correctly
identified after 2 weeks of treatment with the same agent.
Level of specificity was high (83.9%), with moderate sen-
sitivity(65.1%),highPPV(76.1%),andhighNPV(75.4%).
Sensitivity Analyses
In order to assess whether low baseline severity in a sub-
group of patients may confound the results and diminish
the power to show a signal (because about 10% were re-
mitted at baseline), we repeated the analyses on a sub-
group of patients who were at least moderately ill at
baseline (N = 219). We defined ‘‘at least moderately
ill’’ as having a baseline PANSS total score 75 or
more
18andatleastamoderatelevel(score 4)onatleast
2 of 4 psychotic items on the PANSS (conceptual disor-
ganization, suspiciousness, hallucinatory behavior, and
unusual thought content). Results were highly consistent
withtheoriginal analysis.Theoverallpredictive accuracy
was essentially unchanged (slight decline from the origi-
nal 71.8% to 70.8%), and the proportion of patients
deemed early responders slightly increased (from 22.1%
to 25.1%). There was some improvement in sensitivity
(from 41.5% to 45.4%), specificity (from 88.7% to
91.0%), and PPV (from 67.4% to 80%), with decline in
NPV (from 73.0% to 67.7%).
To further assess the robustness of the findings, anal-
yses were repeated using assigned treatment (olanzapine,
risperidone, conventional antipsychotics) as an addi-
tional covariate. Results were unchanged.
Symptom Remission
Compared with early responders, early nonresponders
were less likely to achieve symptom remission (severity
criterion) following 8 weeks of treatment. Although early
responders and early nonresponders did not significantly
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H. Ascher-Svanum et al.Table 1. Comparison of Early Responders and Nonresponders on Baseline Demographic and Clinical Characteristics
Variable
Responders at
2 wk, N = 98
Nonresponders at
2 wk, N = 345 P Value
Mean age (SD) 44.0 (14.2) 43.5 (11.3) .975
Gender: % male 58.2 62.9 .505
Race .335
Caucasian 52 (53%) 200 (58%)
African American 37 (38%) 105 (30%)
Other 9 (9%) 40 (12%)
Married 16 (16%) 52 (15%) .988
Currently employed 17 (17%) 63 (18%) .972
Mean prior episodes 6.2 (6.7) 6.7 (9.7) .959
Past year psychiatric hospital duration .826
None 71 (72%) 243 (72%)
<1 mo 19 (19%) 57 (17%)
1 mo plus 8 (8%) 38 (11%)
Mean PANSS total score, mean (SD) 89.8 (21.6) 84.4 (20.1) .023
PANSS positive subscale mean (SD) 22.5 (6.5) 21.6 (6.2) .201
PANSS negative subscale mean (SD) 221 (6.5) 209 (7.2) .131
PANSS disorganized thoughts subscale mean (SD) 21.9 (6.5) 21.0 (6.2) .225
PANSS impulsivity/hostility subscale mean (SD) 9.7 (3.8) 8.6 (3.6) .004
PANSS anxiety/depression subscale mean (SD) 13.6 (4.5) 12.3 (4.1) .010
Remitted
a at baseline, n (%) 11 (11%) 33 (10%) .244
Inpatient during randomization 2 (2%) 18 (5%) .312
Duration of psychiatric diagnosis (y) 21.4 (13.9) 21.3 (11.7) .959
Age at onset of diagnosis 22.6 (9.7) 22.1 (9.1) .959
Assigned treatment n (%) .886
Olanzapine 36 (37) 129 (37)
Risperidone 34 (35) 105 (30)
Conventional antipsychotics 28 (28) 111 (32)
SF-36
b bodily pain  0.32  0.32 .858
SF-36
b general health  0.48  0.61 .225
SF-36
b mental health  0.95  0.88 .891
SF-36
b physical functioning  0.72  0.72 .546
SF-36
b role—emotional  0.81  0.94 .484
SF-36
b role—Physical  0.56  0.81 .059
SF-36
b social functioning  0.89  1.00 .243
SF-36
b vitality  0.63  0.55 .721
SF-36
b physical heath component score  0.34  0.48 .109
SF-36
b mental health component score  0.95  0.92 .976
Health insurance .363
Medicaid 37 (38%) 130 (40%)
Medicare 28 (29%) 93 (28%)
Private insurance 19 (20%) 37 (11%)
Other insurance 0 (0%) 17 (5%)
Uninsured 13 (13%) 52 (16%)
Note: PANSS, Positive and Negative Syndrome Scale; SF-36, Medical Outcome Survey-Short Form 36.
aRemitted (severity criteria) defined as mild or better scores ( 3) on 8 PANSS items (P1, P2, P3, N1, N4, N6, G5, G9).
18
bStandardized SF-36 score relative to general population norms.
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9.6%, P = .702), the change in symptom remission rate
from baseline to 8 weeks was significantly larger for early
responders (P < .001) because 46.9% of the early res-
ponders and only 27.5% of the early nonresponders
were in remission following 8 weeks of treatment (P <
.001). The increase in remission rate from baseline to
8 weeks for early responders (35.7%) was nearly twice
as high as that for early nonresponders (18.0%).
Level of Functioning
Changes on SF-36 scale scores for the 2 groups from base-
line to 8 weeks of treatment are presented in table 2.
Although the groups did not significantly differ on
any mean scale score at baseline, following 8 weeks of
treatment with the same antipsychotics, the early nonres-
ponders had significantly lower levels of improvement on
the mental health composite score and on 5 of 8 func-
tional domains: mental health, role emotional, social
functioning, physical functioning, and vitality. More spe-
cifically, the early responders, but not the early nonres-
ponders, improved by about one-half a SD (þ0.49,
change from  0.95 to  0.46) on the mental health com-
ponent score and on social functioning (þ0.45, change
from  0.89 to  0.44), suggesting some clinically mean-
ingful changes in early responder’s level of functioning in
these domains. The 2 groups did not significantly differ
on changes in the physical health composite score or on
3physicalhealth–relatedscales:generalhealth,rolephys-
ical, and bodily pain.
Perceptions of Medication Inﬂuence
Scores onthe ROMI forthe2 groupsonthe 5dimensions
of medication influence at 8 weeks are presented in
table 3. Compared with early responders, early nonres-
ponders had significantly (P = .004) lower (worse) scores
following 8 weeks of treatment only on the perceived
medication benefits dimension, which is comprised of 4
items: perceived daily benefits, fear of relapse, side effect
relief, and fulfillment of life goals.
Health Care Costs
Differencesbetweenthegroupsondirecttotalhealthcare
costs and medication and nonmedication costs following
8 weeks of treatment are presented in table 3. The total
direct health care cost was almost twice as high for early
nonresponders as for early responders ($4349 vs $2102,
P = .010). This group difference was primarily driven
by nonmedication costs, which were significantly higher
forearly nonresponders($3726 vs$1533,P < .011), while
the groups did not significantly differ on medication
costs. Significant group differences in direct health care
costs were evident following only 2 weeks of treatment,
and costs for early nonresponders also remained higher
for Weeks 3 through 8. After 2 weeks, early nonrespond-
ers accrued twice ashigh total health care costs compared
with the early responders ($1194 [SD = $1119] vs $581
[SD = $2235], P = .021), driven also by significantly
higher direct nonmedication costs ($1042 [SD = $2213]
vs $451 [SD = $1119], P = .025), without significant dif-
ferences in medication costs ($152 [SD = $125] vs $130
[SD = $83], P > .05).
Table 2. Comparisons of Early Responders and Early
Nonresponders on Change in SF-36 Subscale and Composite
Scores from Baseline to 8 Weeks
Variable
Responders
at 2 wk,
N = 98,
Mean (SD)
Nonresponders
at 2 wk,
N = 345,
Mean (SD) P Value
Changes in SF-36
Mental health þ0.37 (1.20) þ0.08 (1.09) .014
General health þ0.09 (1.01) þ0.08 (0.95) .228
Role/emotional þ0.39 (1.55) þ0.23 (1.44) .020
Role/physical þ0.18 (1.30) þ0.17 (1.25) .218
Social functioning þ0.45 (1.41) þ0.24 (1.22) .035
Bodily pain þ0.29 (1.21) þ0.18 (1.19) .426
Physical functioning þ0.19 (1.34) þ0.01 (1.08) .049
Vitality þ0.40 (1.13) þ0.17 (0.97) .033
Mental health
composite score
þ0.49 (1.30) þ0.20 (1.10) .005
Physical health
composite score
þ0.08 (1.02) þ0.09 (0.88) .495
Note: SF-36, Medical Outcome Survey-Short Form 36.
Table 3. Comparisons of Early Responders and Early
Nonresponders on Perceptions of Medication Benefits and
Estimated Health Care Costs Following 8 Weeks of Treatment
Variable
Responders at
2 wk, N = 98,
Mean (SD)
Nonresponders
at 2 wk,
N = 345,
Mean (SD) P Value
ROMI factor scores
Negative aspects
of medication 1.51 (0.64) 1.50 (0.61) .952
Denial of illness 1.25 (0.47) 1.33 (0.57) .174
Positive external
influence 2.05 (0.71) 1.95 (0.72) .360
Perceived
medication
benefit score 2.52 (0.49) 2.32 (0.57) .004
Stigma 1.21 (0.38) 1.27 (0.52) .156
Estimated health
care costs
Medication costs $569 (435) $623 (479) .276
Nonmedication
costs $1533 (3846) $3726 (7697) .011
Total health care
costs $2102 (3866) $4349 (7809) .010
Note: ROMI, Rating of Medication Influences.
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Although this study’s core finding—that early nonre-
sponse predicts later nonresponse—is well established,
this replication study extends prior research in 3 impor-
tant ways. First, this study includes mostly outpatients
and uses less strict entry criteria than those used in
double-blind, controlled RCTs, thereby increasing the
generalizability of the findings to settings and patients of-
ten excluded from the currently published studies on this
topic. Second, this study also uses an absolute response
criterion (ie, no more than mild severity on all 4 PANSS
psychotic subscore items) to overcome the fact that rel-
ative response criteria are vulnerable to the effect of base-
line scores and may either under- or overestimate the
effect of the antipsychotic. And lastly, this study
assesses—for the first time—the ramifications of early
response/nonresponse to treatment, by assessing clinical
and functional outcomes, subjective patient perceptions,
and health care cost.
This study helps advance the importance of early eval-
uation of patients’ response to antipsychotics for poten-
tial change in regimen from the patient, clinician, family
member, and payer perspectives. It shows that continued
exposure to initial treatment, despite less than minimal
symptom improvement at 2 weeks, not only prolongs
suboptimal treatment unnecessarily but is also associated
with more negative subjective perceptions of medica-
tion’s benefits, with poorer functional outcomes, and
with higher health care costs.
Consistent with prior schizophrenia studies that used
data from RCTs with predominately inpatients,
8–11 the
current study of antipsychotic therapy in the usual
care of predominately outpatients with schizophrenia
also revealed that early nonresponse to treatment is a ro-
bust and accurate predictor of subsequent nonresponse
to continued therapy with the same medication. The cur-
rent study further expands on prior research by showing
that patients who do not experience early response (early
nonresponders following 2 weeks of treatment) demon-
strate significant and clinically meaningful poorer out-
comes in symptomatic, functional, and economic terms
when their treatment is continued with the same antipsy-
chotic medication for an additional 6 weeks. The valida-
tion of previous research may enhance the generalization
of the findings to patients with schizophrenia treated in
outpatient practice settings and underscores the implica-
tions of this clinical marker to usual care where timely
identification of early nonresponders may help minimize
prolonged exposure to suboptimal or ineffective treat-
ment strategies.
This study found that schizophrenia patients with less
than minimal improvement in their symptomatology fol-
lowing 2 weeks of antipsychotic therapy are unlikely to
show at least a minimal improvement at 8 weeks of treat-
ment if treatment continued with the same medication.
Furthermore, the current study found a high level of
specificity (89%) and NPV of 73%, which were maintained
whenthedefinitionofearlyresponsewasalteredfromarel-
ative response (20% reduction in PANSS total score from
baseline) to an absolute response (mild or better on 4 core
psychotic symptoms). Although clinicians are more likely
to monitor patients’ treatment progress using 4 psychotic
itemsthanadministerthe30-itemPANSS,itisnotablethat
a 20% reduction in PANSS total score from baseline to
2 weeks of treatment (‘‘minimal improvement’’) was pre-
viously found to be comparable to a 1-point improvement
on the Clinical Global Impressions-Improvement,
18 as i m -
pler measure widely used by clinicians. Furthermore, from
a clinical perspective, demonstrating high specificity and
NPV is most important because clinicians typically focus
on the nonresponding patients who require ‘‘rescue’’ strat-
egies in the form of changes in current treatment regimens.
Althoughcurrentfindingsarereportedforaheterogeneous
group of outpatients in terms of illness severity, sensitivity
analyses replicated the findings in a subgroup of patients
who were at least moderately ill at baseline.
It is importantto note that althoughearly nonresponse
appears to be a robust predictor of subsequent nonre-
sponsetoinitiated medication,someearlynonresponders
will become subsequent responders following 8 weeks of
treatment (about 27% ‘‘false negatives’’). Future research
is needed to help identify reliable predictors of delayed
response among these ‘‘false negatives’’ to enhance the
accuracy of this treatment response marker. In addition,
current findings do not necessarily imply that an early
switch to another antipsychotic will increase likelihood
of eventual response. This is an empirical question that
will require a study in which early nonrespondersare ran-
domly assigned to double-blind therapy with either a dif-
ferent ‘‘rescue’’ treatment option or continue on the same
initial medication.
Current findings highlight the importance of timely
identification of early nonresponders for potential
change in medication regimen and the impact on out-
comes it could have on the patient, the clinician, the fam-
ily member, and the payer. Early nonresponding patients
are less likely to achieve subsequent symptom remission,
to function at a poorer level within multiple domains in-
cludinggreaterdeficitsinsocialrelationshipsandvitality,
to incur total direct costs that are twice as high as early
responders (driven by high nonmedication costs), and to
perceive medications as less beneficial to them.
It is important to note that despite statistically signif-
icantly greater functional improvements among early
responders compared with early nonresponders, both
groups were still functioning at a poorer level—at least
one-half SD—below the general population norms fol-
lowing8weeksoftreatment.However,theearlyrespond-
ers (but not the early nonresponders) experienced after 8
weeks of treatment a level of functional improvement
equivalent to about one-half a SD, a magnitude that is
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health-related quality-of-life instruments for patients
with chronic diseases.
26 For example, the baseline mental
health and social functioning levels were poorer than the
general population for both early responders and early
nonresponders—about 1 SD below the norm. However,
following 8 weeks of treatment, early responders im-
provedbyaboutone-halfaSDonthementalhealthcom-
ponent score and on social functioning, suggesting some
clinically meaningful changes in early responder’s level of
functioning in these important domains. Further study is
needed, however, to translate the clinical meaningfulness
of gaining one-half SD on SF-36 scores in the treatment
of schizophrenia, especially how such changes may im-
pact patients’ life satisfaction, occupational functioning,
housing arrangements, and other important aspects of
daily life.
In addition, the finding that early nonresponders ap-
pear to perceive medications as less beneficial to them
is of clinical importance because the likelihood of be-
coming medication nonadherent was previously found
(results are drawn from the same study from which
this subsample was drawn) to be greater among schizo-
phrenia patients who believed medications were of low
benefit.
27 Moreover, a recent study
22 showed that a lower
level of perceived beneficial effects of medication is asso-
ciated with a higher rate of early treatment discontinua-
tion. Because better adherence is linked to favorable
long-term outcomes,
28 including reduced risk of relapse
and hospitalization, the current findings suggest that
identification of early nonresponders may be valuable
in the clinical and economic realms for the patients
and other health care decision makers.
The present study has, however, some important lim-
itations. First, this was a post hoc analysis limited to
patients who completed 8 weeks of treatment. There is
a need for additional studies that assess a priori, the pre-
dictiveaccuracyofearlynonresponseasareliablemarker
ofeventualnonresponseamongpatientstreatedwithspe-
cific antipsychotics. Second, this study examined predic-
tive accuracy using conditional probabilities, although
the use of other methods, such as receiver-operator
curves,mayprovideadditionalusefulinformationpartic-
ularly on the impact of using different initial and subse-
quent levels of response at different time points. This
could not be readily done in this analysis due to con-
straints of the study design (patients could and did switch
to other antipsychotics, if clinically warranted, following
8 weeks of treatment). Another important issue is that
early response does not necessarily mean marked im-
provement or remission. To fully consolidate the gains
of a successful antipsychotic therapy will require longer
treatment duration as most patients may take 8–12 weeks
to reach stable symptom improvements.
29,30 Thus, al-
though response at 2 weeks appears to reliably predict
subsequent outcome, we are not in any way suggesting
that patients are remitted or much improved by 2 weeks
if they respond to their medication.
In conclusion, utilizing data from a naturalistic study
of antipsychotics in the treatment of predominately out-
patients with schizophrenia, early nonresponse to treat-
ment was found to accurately predict subsequent
nonresponse to continued treatment with the same anti-
psychoticagentafter8weeks.Furthermore,earlynonres-
ponders demonstrated poorer clinical, functional, and
economic outcomes following 8 weeks of treatment. Cur-
rentfindingssuggestthatidentifyingearlynonresponders
is an important step in effective management of persons
with schizophrenia, a practice that may lead to tailored
therapeutics and help minimize exposure to suboptimal
or ineffective treatment strategies.
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